Immune cells in chronic prostatitis/chronic pelvic pain syndrome: From pathological mechanisms to therapeutic opportunities.

Cell SignalMay 27, 2026 (epub)
Clinical ResearchUrology

Zewen Li, Rui Yan, Yongfeng Lao et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review explores the role of immune cells in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), a prevalent urological disorder. It highlights the involvement of T lymphocytes, macrophages, neutrophils, and mast cells in the disease's pathophysiology, emphasizing their contributions to inflammation and pain. The review outlines potential therapeutic strategies targeting these immune mechanisms.

Key findings

  • Abnormal immune activation is central to the onset and maintenance of CP/CPPS symptoms.
  • Key immune cells include Th1, Th17, Treg cells, M1 and M2 macrophages, neutrophils, and mast cells.
  • The review discusses the Th1/Th17-Treg imbalance and macrophage polarization abnormalities.
  • Potential therapeutic strategies targeting immune cells and signaling pathways are summarized.

Why it matters

Understanding the immune mechanisms underlying CP/CPPS can inform the development of targeted therapies, potentially improving patient outcomes and quality of life. This knowledge is crucial for clinicians managing this complex condition.

Source

PubMed · PMID 42208635

Published in Cell Signal. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Urology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.